In last trading session, Denali Therapeutics Inc. (NASDAQ:DNLI) saw 1.7 million shares changing hands with its beta currently measuring 1.89. Company’s recent per share price level of $73.73 trading at -$1.08 or -1.44% at ring of the bell on the day assigns it a market valuation of $8.84B. That closing price of DNLI’s stock is at a discount of -27.41% from its 52-week high price of $93.94 and is indicating a premium of 69.67% from its 52-week low price of $22.36. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.5 million shares which gives us an average trading volume of 512.50K if we extend that period to 3-months.
For Denali Therapeutics Inc. (DNLI), analysts’ consensus is at an average recommendation of an Overweight while assigning it a mean rating of 2.10. Splitting up the data highlights that, out of 12 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 3 suggested the stock as a Hold whereas 9 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -$0.4 in the current quarter.
Denali Therapeutics Inc. (NASDAQ:DNLI) trade information
Upright in the red during last session for losing -1.44%, in the last five days DNLI remained trading in the red while hitting it’s week-highest on Monday, 06/14/21 when the stock touched $73.73 price level, adding 4.15% to its value on the day. Denali Therapeutics Inc.’s shares saw a change of -11.97% in year-to-date performance and have moved -1.69% in past 5-day. Denali Therapeutics Inc. (NASDAQ:DNLI) showed a performance of 32.89% in past 30-days. Number of shares sold short was 6.48 million shares which calculate 13.68 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of $87.80 to the stock, which implies a rise of 16.03% to its current value. Analysts have been projecting $60.00 as a low price target for the stock while placing it at a high target of $108.00. It follows that stock’s current price would drop -46.48% in reaching the projected high whereas dropping to the targeted low would mean a gain of 18.62% for stock’s current value.
Denali Therapeutics Inc. (DNLI) estimates and forecasts
Statistics highlight that Denali Therapeutics Inc. is scoring comparatively lower than the scores of other players of the relevant industry. The company lost -11.81% of value to its shares in past 6 months, showing an annual growth rate of -390.48% while that of industry is 9.10. Apart from that, the company came lowering its revenue forecast for fiscal year 2021. The company is estimating its revenue growth to increase by 28.60% in the current quarter and calculating 16.70% increase in the next quarter. This year revenue growth is estimated to fall -70.10% from the last financial year’s standing.
9 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of $29.35 million for the same. And 9 analysts are in estimates of company making revenue of $30.89 million in the next quarter that will end on Sep 2021. Company posted $3.78 million and $9.39 million of sales in current and next quarters respectively a year earlier. Analysts are expecting this quarter sales to grow by 676.50% while estimating it to be 228.90% for the next quarter.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 38.50% during past 5 years.
Denali Therapeutics Inc. is more likely to be releasing its next quarterly report in July and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt.
Denali Therapeutics Inc. (NASDAQ:DNLI)’s Major holders
Insiders are in possession of 17.34% of company’s total shares while institution are holding 77.02 percent of that, with stock having share float percentage of 93.18%. Investors also watch the number of corporate investors in a company very closely, which is 77.02% institutions for Denali Therapeutics Inc. that are currently holding shares of the company. Crestline Management, L.P. is the top institutional holder at DNLI for having 19.46 million shares of worth $1.63 billion. And as of Dec 30, 2020, it was holding 16.06% of the company’s outstanding shares.
The second largest institutional holder is Baillie Gifford and Company, which was holding about 12.19 million shares on Dec 30, 2020. The number of shares represents firm’s hold over 10.06% of outstanding shares, having a total worth of $1.02 billion.
On the other hand, Vanguard Total Stock Market Index Fund and Vanguard U.S. Growth Fund are the top two Mutual Funds which own company’s shares. As of Dec 30, 2020, the former fund manager was holding 2.54 million shares of worth $212.45 million or 2.09% of the total outstanding shares. The later fund manager was in possession of 2.35 million shares on Feb 27, 2021, making its stake of worth around $168.84 million in the company or a holder of 1.94% of company’s stock.